Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

Mustang Bio shares are trading sharply higher Monday afternoon. The FDA granted Orphan Drug Designation to its cell therapy, MB-101.

Get today's Mustang Bio stock news. We cover the latest Mustang Bio headlines and breaking news impacting Mustang Bio stock performance.

Calidi Biotherapeutics (NYSE: CLDI) surged 39.47% after hours Tuesday, following renewed investor interest in its innovative cancer treatment developments.

Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and ...

CEO Jensen Huang deserves to be recognized as one of the globe's best. Asking someone to pick just one stock of the thousands of publicly traded companies in the world is a daunting task. First of ...

Taiwan just fired another shot in the battle to slow its surging currencyand global investors may soon feel the ripple. The central bank is considering a rule that would force foreign funds to ...

Review the current Mustang Bio Inc (MBIO:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MBIO is the best investment for you.